Prevalence Study of Iron Deficiency in Patients With Cancer
Not Applicable
- Conditions
- Iron-deficiency
- Interventions
- Diagnostic Test: Iron deficiency testing
- Registration Number
- NCT03924271
- Lead Sponsor
- VIFORFRANCE
- Brief Summary
Despite its high prevalence, a recent study conducted by Prof. Cacoub (unpublished) on the french national health insurance database showed that iron deficiency was an underdiagnosed and under-treated co-morbidity. In inflammatory situations, especially during cancer, the measurement of the transferrin saturation factor is only performed in about 10% of cases whereas this measure is recommended in inflammatory situations including cancer (French Health High Authority 2011)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
- Patient, male or female, over the age of 18
- Patient in an oncology department (any type of tumor, any type of treatment, initiated or not)
- Patient affiliated or beneficiary of a social security system
- Patient with written consent
Exclusion Criteria
- Protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
- Patient hospitalized without consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ONCOLOGY Iron deficiency testing Patient with a cancer
- Primary Outcome Measures
Name Time Method Blood iron status One day ferritin, haemoglobin, transferrin saturation factor
- Secondary Outcome Measures
Name Time Method